|
|
|
|
|
Highlights from the 2023 ASCO Genitourinary Cancers Symposium |
|
|
|
|
|
Rapid Abstract Session: Prostate Cancer
|
|
| Randomized, Double-Blinded Phase II Study of Ketoconazole, Hydrocortisone, and Anti-PSMA Antibody J591 Labeled with 177Lu or 111In in Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0 CRPC)
|
| Scott T. Tagawa, MD, MS, FACP
|
| Scott Tagawa presented the results of a randomized, double-blind phase II study of ketoconazole, hydrocortisone, and anti-PSMA antibody J591 radiolabeled with 177Lu or 111In in patients with high-risk non-metastatic castrate-resistant prostate cancer (nmCRPC).
|
|
|
|
|
|
| Results of a Multicenter, Randomized, Phase 3 Trial of Trimodality Therapy with I-125 Brachytherapy, External Beam Radiation Therapy, and Long- Versus Short-Term ADT for Localized High-Risk Prostate Cancer (TRIP/TRIGU0907)
|
| Atsunori Yorozu, MD, Ph.D.
|
| Atsunori Yorozu discussed the results from TRIP/TRIGU0907, a multicenter, randomized, phase 3 trial of trimodality therapy with I-125 brachytherapy, external beam radiation therapy, and long- versus short-term ADT for localized high-risk prostate cancer.
|
|
|
|
|
|
| Pembrolizumab plus Docetaxel for Patients with mCRPC: Randomized, Double-Blind, Phase 3 KEYNOTE-921 Study
|
| Daniel P. Petrylak, MD |
| Daniel Petrylak discussed the results from KEYNOTE-921, a randomized, double-blind, phase 3 study of pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC). |
|
|
|
|
|
|
|
|
|
|
| Efficacy and Safety of Abiraterone Acetate plus Prednisone and ADT +/- Docetaxel in Older Patients (≥70 Years), with De Novo mCSPC, Compared to Younger Patients (70 Years): The PEACE-1 Trial
|
| Loic Mourey, MD |
| Loic Mourey discussed the results from the PEACE-1 trial, specifically efficacy and safety of abiraterone acetate + prednisone and ADT +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer (mCSPC), compared to younger patients (<70 years).
|
|
|
|
|
|
| First-in-Class Oral Innate Immune Activator BXCL701 Combined with Pembrolizumab in Patients with mCRPC of Small Cell Neuroendocrine Phenotype: Phase 2a Final Results
|
| Rahul Raj Aggarwal, MD
|
| Rahul Aggarwal presented the results of a phase 2a trial evaluating the oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype.
|
|
|
|
|
|
|
Advanced Prostate Cancer: New Targets, New Drugs, New Victories?
|
|
| New Targets, New Concepts for Metastatic Castration-Resistant Prostate Cancer |
| Johann S. De Bono, MD, PhD
|
| Johann De Bono discussed new targets and new concepts for metastatic castration-resistant prostate cancer (mCRPC). Multiple new precision medicine therapeutic strategies are in development and it is envisioned that the next decade will result in further advances in care. |
|
|
|
|
|
|
|
|
|
|
| Treatment Combinations for Patients Starting Androgen-Deprivation Therapy: Building on Recent Victories
|
| Gerhardt Attard, MD, Ph.D.
|
| Gerhardt Attard discussed treatment combinations for patients starting androgen deprivation therapy (ADT). Dr. Attard started by highlighting three key sections of his talk, ADT + second generation ARSI, radiotherapy to the primary tumor, and the addition of docetaxel.
|
|
|
|
|
|
| How to Best Use Current Drugs: Treatment Sequencing and Combinations for Metastatic Castration-Resistant Prostate Cancer
|
| Silke Gillessen, MD |
| Silke Gillessen discussed treatment sequencing and combinations for metastatic castration-resistant prostate cancer (mCRPC). Dr. Gillessen started her presentation by highlighting the current landscape for systemic therapies for mCRPC based on lines of therapy. |
|
|
|
|
|
|
Poster Session: Prostate Cancer
|
|
| Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with ENZA Alone in Subjects with mCRPC
|
| Andrew Laccetti, MD, MS
|
| Andrew Laccetti presented preliminary safety and efficacy data on the combination of enzalutamide with a next generation antigen EPI-7396 in chemotherapy-exposed patients with CRPC prior to exposure to any AR pathway inhibitor.
|
|
|
|
|
|
| Effect of Cerebral Dopamine Metabolism Genetic Polymorphism on Patient-Reported Quality-of-Life: An Analysis of the E3805 CHAARTED Trial
|
| Arjun Gupta, MD
|
| Arjun Gupta presented the results of an ad-hoc analysis of the E3805 CHAARTED trial evaluating the effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life. Rs4680 SNP is associated with lower pain levels and superior quality of life among patients with mHSPC treated with ADT, but not chemohormonal therapy.
|
|
|
|
|
|
|
|
|
|
|
| Factors Related to Men’s Experience with Prostate Cancer Germline Testing
|
| Whang Young, MD, Ph.D.
|
| Whang Young presented a report on the results of their PROGRESS Registry. PROGRESS (Prostate Cancer Genetic Risk, Experience, and Support Study) was developed to gain perspective on patient experience with germline testing in prostate cancer.
|
|
|
|
|
|
| Long-Term Safety and Tolerability of Darolutamide and Duration of Treatment in Patients with nmCRPC from the ARAMIS Rollover Study
|
| Neal D. Shore, MD, FACS |
| Neal Shore discussed the long-term safety and tolerability of darolutamide and duration of treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the ARAMIS Rollover Study.
|
|
|
|
|
|
| Circulating Tumor DNA Identifies Homologous Recombination Deficiency in Bone-Predominant mCRPC Prior to Radium-223 Therapy
|
| David D. Yang, MD
|
| David Yang and colleagues sought to evaluate circulating tumor DNA (ctDNA) for evidence of mutations in genes implicated in successful HR repair, thereby surmounting technical limitations of sequencing bone biopsies. They hypothesized that ctDNA would allow for broader identification of HRD in bone-predominant mCRPC and to assess association with clinical outcomes in a real-world cohort. |
|
|
|
|
|
| Baseline Characteristics Associated with PSA Progression-Free Survival in Patients with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO Study (AFT-19)
|
| Rahul Aggarwal, MD
|
| Rahul Aggarwal presented the results of a secondary analysis of the PRESTO trial evaluating the baseline characteristics associated with progression-free survival in patients with high-risk biochemically relapsed prostate cancer.
|
|
|
|
|
|
| Geographic Variation in Utilization of Doublet Therapy for Metastatic Prostate Cancer
|
| Samuel L. Washington, MD |
| Samuel Washington discussed geographic variation in utilization of doublet therapy for metastatic prostate cancer. Clinical trials for men with metastatic prostate cancer have supported the use of combination therapies to improve survival outcomes, with recent work showing increased benefit of triplet regimens. However, real-world utilization of doublet therapy and variation in use according to geographic region have not been evaluated in detail.
|
|
|
|
|
|
| Impact of Run-in Treatment with Abiraterone Acetate and Prednisone in the MAGNITUDE Study of Niraparib and AAP in Patients with mCRPC and Homologous Recombination Repair Gene Alterations |
| Elena Castro, MD, Ph.D.
|
| Elena Castro presented on the effect of run-in treatment using abiraterone acetate and prednisone on the effect of combination therapy with abiraterone and niraparib for men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations in the MAGNITUDE trial. |
|
|
|
|
|
|
